16 November 2023
2 minutes of reading
Important tidbits:
- During gender-confirming HT, bone mineral density rises in the majority of places for trans individuals.
- The lumbar vertebrae BMD z rating during HT does not increase in those who are assigned female at birth.
According to research published in JAMA Pediatrics, transgender people who receive long-term gender-confirming hormone therapy experience increases in bone mineral density that return to levels seen prior to adolescent reduction.
With the exception of the lumbar spine in individuals who were given male at birth, z scores in people who received long-term usage of gender-affirming hormones matched purification levels. Healio was informed by physiology scholar Marianne van der Loos, MD, of Amsterdam University Medical Centers that this may be because of lower estrogen amounts. In order to increase bone development in people who are assigned to be male at birth, estrogen treatment may be optimized and life counseling provided.
A prospective follow-up cohort study of transgender people who began their medical transition with a gonadotropin-releasing hormone ( GnRH) agonist before the age of 18 and then used gender-confirming HT for at least 9 years was conducted by Van der Loos and colleagues. A study attend at an outpatient clinic resulted in the collection of scientific data, blood examples, and a DXA test. Medical records were used to create retroactive DXA images. The pelvic neck, spine spine, and full hip were all examined at four different time points to obtain actual BMD andBMD z scores.
The study included 75 trans participants, of whom 25 were given male or female births and 50 were feminine at birth. BMD was firm during GnRH agonist therapy in the males who were assigned at birth, and it then rose during gender-confirmingHT. Lumbar spine BMD z score decreased by 0.87 points from benchmark to follow-up because it remained steady during HT. Gender-confirming HT increases BMD z scores at the entire shoulder and pelvic neck, and follow-up results are comparable to those of pretreatment.
There was no correlation between BMI and BMD z report at the spine spine, but each kg/m2 increase was accompanied by a 0.08-point increase in the total hip and pelvic neck, respectively. Although there was a trend toward higher BMD z results with higher estradiol levels, the organizations were not important.
Assessing the relationship between estrogen and BMD in a larger investigation people may be useful in future research, according to van der Loos.
BMD z scores for participants who were given female births decreased during GnRH stimulant therapy and then increased during gender-confirming HT in all three regions. At the end of the follow-up, BMD z scores at the spine spine, overall hip, and pelvic neck were comparable to benchmark. Each 1 mIU/mL of luteinizing estrogen was linked to a 0.03-point drop in BMD z report at the spinal vertebrae at follow-up. Each 1 kg/m2 raise in BMI was accompanied by an increase of 0.1 points in the entire shoulder BMD z rating and a decrease of 0.11 points for the femoral neck. At the spine back, there was no correlation between the BMI and BMD z scores.
According to van der Loos,” BMD z scores prior to beginning GnRH receptor treatment were now decreased in individuals assigned male at birth, so the normal course of BMD advancement in transgender people should get studied.” This may help to clarify how much the hormonal treatment and other factors can be blamed for the finding that follow-up measurements did not match pretreatment levels at the lumbar spine.
More details are available:
At m. [email protected], you may reach MD Marianne van der Loos.
Collapse
Find out more about
